BICYCLE THERAPEUTICS

Company snapshot

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their

• 6 approved product(s) across US/EU regulatory metadata.
• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 57 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for BICYCLE THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for BICYCLE THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   BT8009-230 — Phase 3

2. Jun 8, 2026 Clinical update

   BT8009-230 — Phase 3

3. Jun 8, 2026 Clinical update

   BT8009-100 — Phase 2

4. Jun 8, 2026 Clinical update

   buprenorphine/naloxone — Approved

5. May 26, 2026 Clinical update

   Zelenectide Pevedotin, BT8009 — Phase 2

View all clinical trial activity →

• What is BICYCLE THERAPEUTICS?

  BICYCLE THERAPEUTICS is a pharma organization headquartered in Cambridge, GB. It trades on NYSE under ticker BCYC. Primary therapeutic focus areas include Locally advanced or metastatic urothelial cancer, Nectin-4 Expressing Advanced Malignancies., Advanced Malignancies Associate

• Is BICYCLE THERAPEUTICS publicly traded?

  Yes. BICYCLE THERAPEUTICS is listed with ticker BCYC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does BICYCLE THERAPEUTICS develop or market?

  We link 15 drug profile(s) where BICYCLE THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bicycle-therapeutics#company-drugs.

• What are the latest developments for BICYCLE THERAPEUTICS?

  In the last 12 months our linked public records show 8 trial program update(s) and 4 US patent grant(s) tied to this profile.

• What therapeutic areas does BICYCLE THERAPEUTICS focus on?

  BICYCLE THERAPEUTICS focuses on Locally advanced or metastatic urothelial cancer, Nectin-4 Expressing Advanced Malignancies., Advanced Malignancies Associated with EphA2 Expression based on our analysis of their pipeline programs and drug development activities.